Screener
Indivior Pharmaceuticals, Inc. INDV Pre-Tax Income
Pre-Tax Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028850
FAQ
- What is Indivior Pharmaceuticals, Inc.'s pre-tax income?
- Indivior Pharmaceuticals, Inc. (INDV) reported pre-tax income of $115M in Q1 2026.
- How has Indivior Pharmaceuticals, Inc.'s pre-tax income changed year-over-year?
- Indivior Pharmaceuticals, Inc.'s pre-tax income increased by 94.9% year-over-year, from $59M to $115M.
- What is the long-term trend for Indivior Pharmaceuticals, Inc.'s pre-tax income?
- Over 3 years (2022 to 2025), Indivior Pharmaceuticals, Inc.'s pre-tax income has grown at a 40.6% compound annual growth rate (CAGR), from -$86M to $239M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.
Ask your AI about Indivior Pharmaceuticals, Inc.'s pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude